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Association of a single nucleotide 
polymorphism in the CD209 (DC-
SIGN) promoter with SARS severity
Key Messages
1. In this genetic risk-association 
study involving about 1300 
subjects, SARS patients carrying 
the DC-SIGN promoter -336G 
variant had lower risk of having 
higher lactate dehydrogenase levels 
on admission, an independent 
prognostic indicator for severity of 
SARS-CoV infection.
2.	 In	 vitro functional studies 
demonstrated that the DC-SIGN 
-336G promoter provided a less 
effective binding site and lower 
promoter activity, which may 
lead to reduced DC-SIGN protein 
expression and hence may contribute 
to a reduced immune-response 
with reduced lung injury during the 
progression of SARS infection.
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Introduction
Severe acute respiratory syndrome (SARS) is an acute respiratory disease 
resulting from infection by a novel coronavirus (SARS-CoV). Dendritic cell–
specific ICAM-3 grabbing non-integrin (DC-SIGN) is a C-type lectin expressed 
on the surface of subsets of human DCs and alveolar macrophages, and functions 
both as a cell adhesion and as a pathogen recognition receptor to facilitate 
infection. Pseudo-particles presenting SARS-CoV spike protein can bind to 
DC-SIGN. Homozygous genotypes of the tandem-repeat polymorphism of 
DC-SIGNR, which share 77% similarity with DC-SIGN, are protective against 
SARS-CoV infection. 
 As a pathogen recognition receptor, DC-SIGN allows DCs to capture and 
interact with numerous pathogens, such as Mycobacterium	tuberculosis, HIV-1 
and dengue viruses, etc. As an adhesion receptor, it plays an important role in many 
DC functions, such as the DC–T-cell interaction and DC migration. Host genetic 
factors have been shown to result in differences in host susceptibility to SARS 
infection and outcome of the disease. These include the genetic polymorphisms 
in L-SIGN, MBL, HLA-B and HLA-DRB1 for host susceptibility; and 
polymorphisms in ACE1, ICAM3, MXA and FcγRIIA for disease outcome.
 In the DC-SIGN	 promoter region, a putative functional single nucleotide 
polymorphism (SNP), -336A>G, (rs4804803) affecting an Sp1-like transcription 
factor binding site has been described.1 This SNP was found to affect the 
transcription activity of DC-SIGN in	 vitro. It has significant association with 
susceptibility for HIV-1 and	M	tuberculosis infections, and with the severity of 
dengue.1-3 
 As the SARS-CoV spike proteins share great similarity with HIV envelope 
proteins, we hypothesised that the DC-SIGN promoter SNPs may also be 
associated with the severity of SARS-CoV infection. Therefore, we analysed the 
promoter SNPs of DC-SIGN for genetic association to SARS-CoV using a large 
case-control study, and performed in	vitro functional studies to verify the effect 
of DC-SIGN promoter SNPs on promoter activity and its influence on DC-SIGN 
expression in	vivo.
Methods
Study design
This case-control genetic association study was conducted from June 2006 to 
May 2008 to examine the contribution of DC-SIGN -336A/G SNP to SARS-CoV 
infection and/or association with SARS patients’ clinico-pathological outcomes. 
 A total of 824 SARS patients confirmed by serology and/or RT-PCR for 
SARS were recruited from the Pamela Youde Nethersole Hospital, Princess 
Margaret Hospital, United Christian Hospital, Queen Mary Hospital, Alice Ho 
Miu Ling Nethersole Hospital, and Prince of Wales Hospital. The 471 controls 
included 281 household contacts (genetically unrelated household members of 
SARS patients) who remained unaffected and sero-negative, and 190 health care 
workers who had worked in SARS wards but remained disease-free and sero-
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negative. All the subjects and controls were Chinese. 
Main outcome measures
The clinical data of the SARS cases were retrospectively 
obtained from the Hospital Authority, with permission from 
all attending clinicians. The data included age, sex, length 
of hospital stay, extent of intensive care unit treatment, 
whether patients received assisted ventilation, any form of 
steroid treatment or intravenous immunoglobulin, as well 
as final outcomes in terms of survival and death. Results of 
haematological and biochemical laboratory investigations 
on admission included the haemoglobin level, absolute 
lymphocyte count, platelet count, white blood cell count; and 
biochemical indices of alanine-aminotranseferase, albumin, 
globulin, creatinine-kinase, lactate-dehydrogenase, urea, 
sodium, potassium and serum creatinine. 
Study instruments
Genotyping for DC-SIGN -336A/G promoter SNP was 
performed using Allelic Discrimination TaqMan Assay 
(Applied Biosystems). Proper controls and replicates 
were included for quality control. DC-SIGN -336A/G 
genotyping results were also integrated with the ICAM3 
+443T/C genotyping results4 for combined genotype risk-
association analysis. 
	 In	 vitro functional studies of DC-SIGN -336A/G 
promoter SNP was performed using (1) an electrophoretic 
mobility shift assay (EMSA) and (2) a luciferase-reporter 
promoter activity assay. The EMSA was used to investigate 
the differential binding of nuclear extract to the -336A/G 
polymorphic site. Complementary oligonucleotide pairs 
harbouring either -336A or -336G of the DC-SIGN promoter 
were 32P-end-labelled and were incubated with HeLa cell 
nuclear extracts. Consensus Sp1 and AP2 probes were 
used to compete with -336A or -336G probe for nuclear 
extract binding. Before incubation, unlabelled -336A or 
-336G oligonucleotide probes were added to compete for 
the radiolabelled probe reaction mixture at 25 or 50 times 
molar excess. The protein-DNA complexes were resolved 
using non-denaturing polyacrylamide gel electrophoresis.
 The luciferase-reporter promoter activity assay was 
used to examine whether -336A or G allele would give 
rise to lower promoter activity. One mg of luciferase-
reporter DC-SIGN promoter construct plasmid and 0.1 
mg of Renilla plasmid were transfected into the HeLa cell 
lines using lipofectamine 2000 (Invitrogen). After transient 
transfection for 24 hours, the cells were harvested and the 
activity of the promoter constructs assayed using the dual-
luciferase reporter assay system (Promega). To determine 
promoter activity, firefly luciferase-expression levels were 
normalised against Renilla-luciferase levels. The luciferase 
expression levels between pGL3-basic/DC-SIGN-336A 
and pGL3-basic/DC-SGIN-336G were compared. The 
pGL3-basic plasmid was used as a negative control. Light 
emission was measured; the experiments were performed 
as three sets of triplicates. Results were compared using the 
Student’s t test.
 The expression level of DC-SIGN in the peripheral 
blood mononuclear cells (PBMCs) derived DCs (which 
carried different -336A/G genotypes) was compared. CD14+ 
monocytes were isolated from PBMCs and then cultured 
in the presence of GM-CSF and IL-4, and were harvested 
after 5 days of culture for DC-SIGN expression analysis 
by flow cytometry. The percentage and mean fluorescence 
level of positive cells were measured by counting the cells 
demonstrating a higher signal than the control.
Statistical analysis
For risk-association analysis, genotype distributions of 
the patients and controls were compared using the c2 test; 
strength of association was measured using an odds ratio 
(OR) and 95% confidence intervals (CI). Genotyping 
results were checked for Hardy-Weinberg equilibrium. For 
in	vitro studies, statistical significance was calculated using 
the Student’s t	test. The c2 test was used to test for possible 
association with nominal clinical outcome measures. For 
numerical variables, each was first analysed by Student’s t 
test. If significant, it was further stratified and then examined 
using the c2 test. Logistic regression analysis was applied to 
adjust for age and gender. 
Results
Genetic susceptibility analysis
A total of 824 SARS cases and 471 controls were 
successfully genotyped. The SNP was in Hardy-Weinberg 
equilibrium in both patients and controls. There was no 
significant difference between patients and controls in 
terms of genotypes (P=0.93) or allele frequency (P=0.81). 
Trend of association was not observed. Therefore, further 
investigations with more healthy controls were not 
performed.
Severity association analysis
Because only three subjects were homozygous for GG 
polymorphism, we combined GG and GA heterozygous 
genotypes for severity association analysis. The 
mean±standard error of the mean of lactate dehydrogenase 
(LDH) levels in the AA group was significantly higher 
than that in GG/GA group (1.14±0.03 vs 1.03±0.04, 
P=0.019), suggesting that LDH levels were associated 
with the DC-SIGN-336A/G SNP. All other parameters 
tested (ie ALT, albumin, creatinine kinase, haemoglobin, 
lymphocyte, platelet, white blood cell and globulin) 
showed no significant association with the genotype groups 
by independent t test (Table 1). To examine the risk level, 
patients were categorised into two subgroups, namely high 
and low LDH levels (Table 2). The frequency of G-carriers 
in persons with low LDH levels was significantly higher 
than in those with high LDH levels (18.46% vs 8.33%, 
P=0.015, OR=0.40, 95% CI=0.19-0.85); the DC-SIGN-
336G allele was overrepresented in the low LDH level 
group than in the high LDH level group (9.49% vs 4.17%, 
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P=0.014, OR=0.41, 95% CI=0.20-0.86). These results 
suggested that G carriers had a 2.44-fold greater chance 
of having lower LDH levels. The association remained 
significant after adjustment for age and gender as well as 
genetic relationships of the subjects.
DC-SIGN and ICAM3 combined genotype analysis
The genotyping results of DC-SIGN -336A/G SNP of the 
SARS patients was combined with our previously reported 
genotyping results of ICAM3 Asp143Gly (+443T/C) 
SNP4 (Table 3). The wild-type genotypes of both SNPs 
(ie ICAM3+443TT/DC-SIGN-336AA genotypes) were of 
highest frequency in the cohort. Analysis of the mean LDH 
level on admission of the combined genotypes showed 
that combined genotype +443CC/-336AA was the highest. 
Non-parametric t-test of +443CC/-336AA genotype and the 
wild-type genotype groups showed significant difference in 
the LDH level (P=0.033). The frequency of patients with 
high LDH levels in each combined genotype was compared 
to that of the wild-type +443TT/-336AA genotype using 
the χ2 test (Table 3). Significant association of the overall 
genotypes was observed (P=0.024). Comparison of the 
wild-type genotype with each combined genotype also 
showed association of the combined +443CC/-336AA 
genotype with higher LDH levels (P=0.021, OR=4.34, 95% 
CI=1.34-14.12), although the number of cases having the 
combined genotype was small (n=12). Multivariate logistic 
regression analysis for synergistic effect between the SNPs 
indicated that interaction between the two SNPs was not 
significant (P=0.845).
Electrophoretic mobility shift assay and promoter 
activity assays
DC-SIGN -336A/G was found to harbour the Sp-1 
transcription factor binding site, with the - 336G allele 
harbouring the binding site, but being abolished with the 
Parameters G-carrier (GG/GA) Non G-carrier (AA) P value*
No. Mean SEM No. Mean SEM
Alanine aminotransferase 127 0.66 0.05 656 0.82 0.04 0.093
Albumin 127 40.19 0.38 655 39.78 0.17 0.337
Creatine kinase 133 133.22 16.76 659 162.03 14.47 0.384
Haemoglobin 134 13.53 0.12 687 13.28 0.07 0.090
Lymphocyte 134 0.94 0.03 683 0.92 0.02 0.501
Platelet 134 169.79 4.64 687 180.16 2.51 0.051
White blood cell 134 5.63 0.18 687 5.67 0.09 0.869
Globulin 93 34.76 0.48 537 33.87 0.21 0.107
Lactate dehydrogenase level (ratio 
of upper normal reference)
116 1.03 0.04 565 1.14 0.03 0.019
Table 1. Univariate association between laboratory parameters on admission and genotypes of DC-SIGN-336A/G among SARS 
patients
* Two independent sample comparison between patients being heterozygous and homozygous for the least prevalent allele (G-carrier, GA/GG) versus patients 
being homozygous for the most prevalent allele (non G-carrier, AA)
* Cutoff value of normalised LDH level is 1.6 fold of upper normal reference
Variable Lactate dehydrogenase levels on admission* P value Odds ratio (95% CI)
Genotype Low (n=585) High (n=96)
GG 3 (1%) 0 (0%) - -
GA 105 (18%) 8 (8%) 0.047 -
AA 477 (82%) 88 (92%) - -
Non G-carrier (AA) 477 (82%) 88 (92%) Reference
G-carrier (GA/GG) 108 (18%) 8 (8%) 0.014 0.40 (0.19-0.85)
Alleles Low (n=1170) High (n=192)
A 1059 (91%) 184 (96%) Reference
G 111 (9%) 8 (4%) 0.015 0.41 (0.20-0.86)
Table 2. Frequencies of DC-SIGN-336A/G genotypes and alleles in subgroups of SARS patients
Combined genotype LDH level* P value† Odd ratio (95% CI)
ICAM3 Asp143Gly (+443T/C) DC-SIGN -336A/G High (n=95) Low (n=582)
TT AA 62 (65%) 377 (65%) - Reference
TT AG 6 (6%) 89 (15%) 0.039 0.41 (0.17-0.98)
TT GG 0 (0%) 3 (1%) 1.000 -
TC AA 20 (21%) 90 (15%) 0.286 1.35 (0.78-2.35)
TC AG 2 (2%) 15 (3%) 1.000 -
CC AA 5 (5%) 7 (1%) 0.021 4.34 (1.34-14.12)
CC AG 0 (0%) 1 (0%) 1.000 -
Table 3. χ2 tests for lactate dehydrogenase (LDH) level and combined ICAM3/DC-SIGN genotyping of all patients
* Cutoff value of normalised LDH level is 1.6 fold of upper normal reference 
† P=0.024 for overall combined genotype, df=6
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-336A allele.1 Our EMSA results showed that the G probe 
(lane 13) had stronger binding capacity to the nuclear 
extract compared to the A probe (lane 8) [Fig 1]. The 
binding capacity of the G probe was effectively competed 
by the Sp1 consensus probe (lane 17) and by the unlabelled 
cold G probe (lane 15). This suggested that the DC-SIGN 
-336A/G SNP affected the binding of Sp1 present in the 
nuclear extracts. Results from luciferase reporter assays on 
the DC-SIGN promoter constructs containing the -336A/
G SNP showed that the G allele promoter construct had 
significantly lower promoter activity compared to the A 
allele promoter construct (-336G:-336A=3.8:1, P=0.011) 
[Fig 2]. 
 Our EMSA and promoter activity results suggested that 
transcription factor binding sites, such as Sp1, may span 
Fig 1. Electrophoretic mobility shift assay of Sp1 consensus, AP2 consensus, CD209 -336A and -336G probes using HeLa nuclear 
extract
The upshifted bands are indicated by arrows. The relative intensity of upshifted bands is plotted. The band intensity in lanes 3 and 6 
are used to normalise against that in lanes 2 and 5 respectively, whereas the band intensity in lane 12 is used to normalise against that 
in lanes 8 to 11 and 13 to 18. Hence, Lanes 3, 6, and 12 are assigned an arbitrary relative value of 1. Bars denote standard deviations. 
The upshifted bands could be competed by respective cold competitor probes. The intensity of the upshifted band of DC-SIGN -336G 
probe (lane 14) is stronger than that of -336A probe (lane 8). The upshifted band of -336G probe is competed by cold -336G probe more 
effectively than by cold -336A probe (lanes 15 and 16), suggesting that -336G allele has stronger binding affinity to HeLa nuclear proteins 
than -336A allele
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over the -336A/G SNP and hence modulate transcriptional 
activity. Our findings are in concordance with that reported 
by Sakuntabhai et al,1 supporting the transcription regulatory 
role of the DC-SIGN -336A/G SNP. 
DC-SIGN expression in PBMC derived DCs
On screening 20 consecutive PBMC samples, only two 
were found to carry the -336AG genotypes, whereas the rest 
were the homozygous -336AA genotype. The homozygous 
-336GG genotype was difficult to obtain as it contributed 
<1% in our population. As a result, two homozygous AA 
and two heterozygous AG genotypes PBMC samples were 
used for deriving DCs, which were subsequently used for 
detection of DC-SIGN expression by flow cytometry. Our 
results showed that the expression of DC-SIGN in PBMC 
derived DCs with the heterozygous -336AG genotype was 
not significantly different from that with -336AA genotype 
(P=0.767, t-test) [Fig 3]. However, the number of cases 
was small and did not allow conclusions to be made. 
Furthermore, the effect of genotype on surface expression 
of DC-SIGN may only be significant with the homozygous 
-366GG genotype, which we were unable to study owing to 
the rarity of this genotype.
Discussion
The G allele of the DC-SIGN -336A/G SNP has been 
shown to play a protective role against parenteral HIV-
1 infection in European-American populations,3 against 
dengue in Thailand,1 and confer a low risk of tuberculosis 
in African populations.2 Although the -336A/G SNP was 
not associated with susceptibility to SARS infection, the G 
allele of this SNP was associated with lower LDH levels 
in SARS patients being admitted to hospital apart from 
being independently associated with good prognosis for 
the disease.4 The association remained significant after 
adjustment for patient age and gender in both overall cases 
and an unrelated patient subset.
 Increase in serum LDH activity was postulated to be a 
result of massive tissue destruction during the acute phase 
of SARS-CoV infection. A high LDH level on admission 
was an independent prognostic indicator for severity of 
SARS infection and could help clinicians predict adverse 
clinical outcomes.4 A high LDH level reflected tissue 
necrosis related to immune hyperactivity in SARS. A 
cytokine and chemokine storm occurs with a significant 
elevation of T-helper cell cytokine IFN-γ, inflammatory 
cytokines and Th1 IFN-γ-induced protein-10 during the 
early phase of SARS-CoV infection. The respiratory tracts 
of affected individuals who died during the first 10 days 
of illness showed diffuse alveolar damage with a mixed 
alveolar infiltrate, lung oedema and hyaline membrane 
formation indicating lung injury during progression of the 
disease.
 Our EMSA and promoter activity results showed 
lower transcription activity of the -336G allele of DC-
SIGN promoter compare to the -336A allele, suggesting 
that -336A/G has a functional role of in transcriptional 
regulation of DC-SIGN. Sp1 is a possible transcription 
factor binding site spanning the -336A/G SNP. Our findings 
are in concordance with those reported by Sakuntabhai et 
al1 and suggest that individuals with the G allele might be 
less immune-responsive to SARS-CoV. Lower G-allele 
promoter activity may result in lower levels of DC-SIGN 
protein expressed, resulting in a lower T-cell response and 
reduced cytokine and chemokine secretion infiltrating the 
alveoli. Thus, the G allele of DC-SIGN -336A/G might 
Fig 2. Luciferase assay results of the DC-SIGN -336A (pGL3-
basic/DC-SIGN-336A) and -336G (pGL3-basic/DC-SIGN-336G) 
promoter constructs in HeLa cells
Results are the means from three independent triplicate 
experiments. The luciferase activity readings of -336A construct 
is normalised against that of -336G construct which is assigned 
an arbitrary relative value of 1. Luciferase levels for -336G 
are significantly lower (P=0.011, Student’s t test with unequal 
variance). Error bars denote standard deviations
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Fig 3. Comparison of mean fluorescence level of DC-SIGN of 
dendritic cells having -336AA or -336AG genotype
Difference in DC-SIGN level is not significant (P=0.767, Student’s 
t test). Error bars denote standard deviations
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protect the lung from injury during the progression of 
SARS infection.
 Interestingly, the frequency of the minor allele 
-336G identified varied in different ethnic groups; Asian 
populations have the lowest frequency. The frequency of the 
minor allele -336G in Chinese (8.7%) was similar to that in 
Thais (8%),1 but was significantly lower than in European 
Caucasians, Africans, and American-Africans (>20%).1,2 
This genetic heterogeneity between different populations 
suggests that the DC-SIGN SNP might be associated with 
genetic predisposition to disease. Moreover, the significant 
association of the DC-SIGN SNP to various infectious 
diseases suggests that the genetic difference may be caused 
by natural selection of individuals who survived lethal 
disease/pathogen challenges.
 Combined genotype analysis of ICAM3 +443T>C 
and DC-SIGN -336A>G showed that overall combined 
genotypes were significantly associated with disease 
severity. We previously reported that ICAM3 +443C 
carriers were associated with high LDH levels on admission. 
This study found that homozygous -336AA subjects were 
associated with high LDH levels on admission compared to 
-336G carriers. The combined +443CC/-336AA genotype 
was in agreement with this high LDH level association. 
Patients with this +443CC/-336AA genotype had a 4.3-fold 
greater risk than standardised LDH levels on admission. 
Nonetheless, multivariate logistic regression analysis was 
unable to demonstrate any synergistic effect between the 
two SNPs. 
 In summary, a SNP of DC-SIGN -336A/G is associated 
with LDH levels on admission, which is an independent 
prognostic indicator for the severity of SARS. This 
functional SNP affects the promoter activity of DC-SIGN 
and may alter gene expression and hence host immune 
response. 
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